Skip to main navigation

Close

About Us
Our Science
- Publications
Pipeline
Patients
Investors
Culture & Careers
Contact Us

COVID-19 Information
Privacy Policy
Terms of Use
Do Not Sell My Personal Information

Follow Us

About Us
Our Science
- Publications
Pipeline
Patients
Investors
Culture & Careers
Contact Us

Investor Calendar

Overview
Press Releases
Events and Presentations
Stock Information
- Stock Quote & Chart
- Analyst Coverage
SEC Filings
Governance
Investor Resources

Upcoming Events

Jun 13, 2023 at
10:40 AM PDT

Goldman Sachs 44th Annual Global Healthcare Conference

Click here for webcast

Add to Google Calendar

Presentations

Alector May 2023 Corporate Presentation

Repeat IV and SC Dosing of the Anti-Sortilin Antibody AL101

Characterization of Suppressive Myeloid Cells in Solid Tumors to Refine Disease Selection in a Phase 1 Study of The Multi-Siglec Inhibitor AL009

AL009 is a Multi-Siglec Inhibitor Engineered to Bind Myeloid Cells That Enhances Innate and Adaptive Immunity to Cancer

Twelve-Month Results from the INFRONT-2 Phase 2 Open-Label Study of latozinemab (AL001) in Frontotemporal Dementia Patients with a C9orf72 Mutation

Update on the INFRONT-2 Phase 2 Study of AL001 in Frontotemporal Dementia Patients Carrying a Granulin Mutation (FTD-GRN)

AL009, a Fusion Protein and Multi-Siglec Inhibitor, Repolarizes Suppressive Myeloid Cells and Potentiates Anticancer Effects

A First-In-Human Study of the Anti-Sortilin Antibody AL101

A Phase 1 Study of AL003 in Healthy Volunteers and Participants With Alzheimer’s Disease

Design of INFRONT-3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL001 in FTD-GRN

Past Events

May 24, 2023 at
11:00 AM EDT

H.C. Wainwright with Alector

Click here for webcast

May 10, 2023 at
2:20 PM PDT

BofA Securities Health Care Conference 2023

Click here for webcast

Mar 28, 2023 at
12:00 PM EDT

Stifel 2023 CNS Days

Click here for webcast

Be the first to hear about our latest discoveries.

About Us
Our Science
- Publications
Pipeline
Patients
Investors
Culture & Careers

Follow Us

COVID-19 Information
Privacy Policy
Terms of Use
Do Not Sell My Personal Information

Copyright Alector, Inc. 2023.

The information regarding our therapeutic candidates and the patients they are intended to treat on this site is intended only for residents of the U.S.

Close

Are you sure you want to leave?

You are about to leave the Alector site. Please note our privacy policy won’t apply to these third-party sites.

Continue

Cancel